Brian Abrahams
Stock Analyst at RBC Capital
(2.40)
# 2,524
Out of 5,131 analysts
445
Total ratings
46.31%
Success rate
-0.99%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $103 | $73.09 | +40.92% | 2 | Dec 16, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $160 → $180 | $132.66 | +35.69% | 24 | Dec 8, 2025 | |
| SION Sionna Therapeutics | Downgrades: Underperform | $24 | $36.34 | -33.96% | 2 | Dec 1, 2025 | |
| PTCT PTC Therapeutics | Downgrades: Sector Perform | $82 → $91 | $77.59 | +17.28% | 23 | Dec 1, 2025 | |
| NMRA Neumora Therapeutics | Upgrades: Outperform | $4 → $7 | $2.22 | +215.32% | 7 | Dec 1, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $25 → $22 | $9.20 | +139.26% | 6 | Nov 21, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $19 → $18 | $14.84 | +21.29% | 5 | Nov 14, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $55 → $53 | $7.99 | +563.33% | 9 | Nov 13, 2025 | |
| ATYR aTyr Pharma | Maintains: Sector Perform | $1.5 → $1 | $0.68 | +46.41% | 2 | Nov 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $10 → $11 | $8.91 | +23.46% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.33 | +50.38% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $20 | $13.88 | +44.09% | 10 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $32 | $33.11 | -3.35% | 13 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $32 | $26.59 | +20.35% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $58 | $41.23 | +40.67% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $423 → $415 | $460.59 | -9.90% | 56 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $8.20 | +131.85% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $70 | $77.65 | -9.85% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $105 | $122.60 | -14.36% | 34 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $217 → $210 | $185.63 | +13.13% | 41 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $704 → $708 | $768.00 | -7.81% | 34 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $81 → $84 | $106.33 | -21.00% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $67 → $10 | $18.09 | -44.72% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $21.14 | +8.80% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $7.09 | +83.36% | 19 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.10 | +1,404.51% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $23.70 | +254.43% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $15.21 | +103.81% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $176.82 | -19.13% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $32.69 | +22.36% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $12.92 | +16.10% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $3.76 | +139.36% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $24.37 | - | 4 | Dec 4, 2017 |
Kymera Therapeutics
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $73.09
Upside: +40.92%
Neurocrine Biosciences
Dec 8, 2025
Maintains: Outperform
Price Target: $160 → $180
Current: $132.66
Upside: +35.69%
Sionna Therapeutics
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $36.34
Upside: -33.96%
PTC Therapeutics
Dec 1, 2025
Downgrades: Sector Perform
Price Target: $82 → $91
Current: $77.59
Upside: +17.28%
Neumora Therapeutics
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $2.22
Upside: +215.32%
Contineum Therapeutics
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $9.20
Upside: +139.26%
Aardvark Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $14.84
Upside: +21.29%
Corbus Pharmaceuticals Holdings
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $7.99
Upside: +563.33%
aTyr Pharma
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.68
Upside: +46.41%
Prothena Corporation
Nov 7, 2025
Maintains: Sector Perform
Price Target: $10 → $11
Current: $8.91
Upside: +23.46%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.33
Upside: +50.38%
Nov 7, 2025
Maintains: Outperform
Price Target: $21 → $20
Current: $13.88
Upside: +44.09%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $28 → $32
Current: $33.11
Upside: -3.35%
Nov 6, 2025
Maintains: Outperform
Price Target: $34 → $32
Current: $26.59
Upside: +20.35%
Nov 4, 2025
Maintains: Outperform
Price Target: $55 → $58
Current: $41.23
Upside: +40.67%
Nov 4, 2025
Maintains: Sector Perform
Price Target: $423 → $415
Current: $460.59
Upside: -9.90%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $8.20
Upside: +131.85%
Nov 3, 2025
Maintains: Outperform
Price Target: $60 → $70
Current: $77.65
Upside: -9.85%
Oct 31, 2025
Maintains: Sector Perform
Price Target: $100 → $105
Current: $122.60
Upside: -14.36%
Oct 31, 2025
Maintains: Outperform
Price Target: $217 → $210
Current: $185.63
Upside: +13.13%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $704 → $708
Current: $768.00
Upside: -7.81%
Oct 29, 2025
Maintains: Sector Perform
Price Target: $81 → $84
Current: $106.33
Upside: -21.00%
Sep 29, 2025
Downgrades: Sector Perform
Price Target: $67 → $10
Current: $18.09
Upside: -44.72%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $21.14
Upside: +8.80%
Jun 30, 2025
Reiterates: Outperform
Price Target: $13
Current: $7.09
Upside: +83.36%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.10
Upside: +1,404.51%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $23.70
Upside: +254.43%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $15.21
Upside: +103.81%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $176.82
Upside: -19.13%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $32.69
Upside: +22.36%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $12.92
Upside: +16.10%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $3.76
Upside: +139.36%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $24.37
Upside: -